Clinical Trials Browser

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2 Recruiting

35 enrolled

Dermatologic

Melanoma

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

880 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT07356245 2026-04-15

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Phase 2 Recruiting

44 enrolled

DermatologicLymphoidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Phase 2 Recruiting

22 enrolled

DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06414590 2026-04-14

Neoadjuvant Tebentafusp for Uveal Melanoma

Phase 2 Recruiting

19 enrolled

Dermatologic

Uveal Melanoma

NCT06698822 2026-04-14

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Phase 2 Recruiting

20 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT05136196 2026-04-13

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Phase 2 Recruiting

150 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05913388 2026-04-13

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

92 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT06961006 2026-04-13

INTerpath-012

Phase 2 Recruiting

160 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02621021 2026-04-01

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

170 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

29 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT05070403 2026-04-01

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Phase 2 Recruiting

25 enrolled

Dermatologic

Carcinoma, Squamous Cell, Skin Neoplasms

NCT05524935 2026-04-01

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Phase 2 Recruiting

37 enrolled

Dermatologic

Uveal Melanoma

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Phase 2 Recruiting

90 enrolled

Dermatologic

Melanoma

NCT06854653 2026-03-31

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2 Recruiting

115 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT07276386 2026-03-31

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

Phase 2 Recruiting

18 enrolled

Dermatologic

Uveal Melanoma

NCT06623461 2026-03-27

Canbiome2

Phase 2 Recruiting

128 enrolled

Dermatologic

Melanoma

NCT05929664 2026-03-24

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Phase 2 Recruiting

70 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT03521830 2026-03-20

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Phase 2 Recruiting

57 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT06981325 2026-03-11

CEMI-first

Phase 2 Recruiting

34 enrolled

Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Phase 2 Recruiting

100 enrolled

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT06771544 2026-03-10

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Phase 2 Recruiting

14 enrolled

Dermatologic

Melanoma

NCT07448831 2026-03-09

NeoSenti

Phase 2 Recruiting

49 enrolled

Dermatologic

Melanoma

NCT07057596 2026-03-06

NEO-TB

Phase 2 Recruiting

19 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT07449754 2026-03-04

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Phase 2 Recruiting

45 enrolled

Dermatologic

Melanoma

NCT07072728 2026-03-03

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

Phase 2 Recruiting

87 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Adjustment Disorders, Breast Neoplasms, Kidney Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07310784 2026-03-03

A Phase II Trial of LM103 in Advanced Melanoma

Phase 2 Recruiting

92 enrolled

Dermatologic

Advanced Melanoma

NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Phase 2 Recruiting

50 enrolled

DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06070012 2026-02-27

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Phase 2 Recruiting

44 enrolled

Dermatologic

Uveal Melanoma

NCT06627244 2026-02-23

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Phase 2 Recruiting

30 enrolled

Dermatologic

Uveal Melanoma

NCT06999980 2026-02-19

Neo IRENIE

Phase 2 Recruiting

494 enrolled

Dermatologic

Melanoma

NCT05496036 2026-02-18

MCC

Phase 2 Recruiting

15 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT04594187 2026-02-17

MelPORT

Phase 2 Recruiting

168 enrolled

Dermatologic

Melanoma

NCT05155033 2026-02-17

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Phase 2 Recruiting

20 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT07288073 2026-02-13

TIL Therapy in cSCC and MCC

Phase 2 Recruiting

14 enrolled

Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06330064 2026-02-12

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Phase 2 Recruiting

520 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Recurrence, Colorectal Neoplasms, Endometrial Neoplasms

NCT07230613 2026-02-11

NEOREM-NEO-1

Phase 2 Recruiting

50 enrolled

Dermatologic

Melanoma

NCT06548789 2026-02-06

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

Phase 2 Recruiting

35 enrolled

Dermatologic

Melanoma

NCT06953089 2026-02-06

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Phase 2 Recruiting

492 enrolled

DermatologicGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT06624475 2026-02-05

NEON

Phase 2 Recruiting

30 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT03340129 2026-02-02

ABC-X

Phase 2 Recruiting

218 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06365619 2026-01-29

NeoRelapse

Phase 2 Recruiting

25 enrolled

Dermatologic

Melanoma

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

740 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07349303 2026-01-21